Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma
A phase 1/2 trial of Pembrolizumab, Ipilimumab in melanoma and uveal melanoma, run by BioInvent International AB, active and no longer recruiting.
Overview
Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma is a phase 1/2 interventional study registered as NCT06784648 by BioInvent International AB, with 35 participants planned, started 2024-12-11 and due to reach its primary completion in 2025-12-30. Interventions recorded: pembrolizumab (KEYTRUDA®), BI-1607, Ipilimumab (YervoyTM, 50 mg/10 mL solution). Conditions listed: Melanoma Metastatic, Melanoma of Skin, Melanoma BRAF V600E/K Mutated, Melanoma Recurrent. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialBI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)
Shares BioInvent International, Melanoma, Pembrolizumab.
- TrialA Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
Shares Uveal melanoma, Melanoma, Pembrolizumab.
- TrialA Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P
Shares Uveal melanoma, Ipilimumab, Melanoma.
- TrialBI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors
Shares BioInvent International, Pembrolizumab.
- JournalMelanoma research
Shares Uveal melanoma, Melanoma.
- JournalPigment cell & melanoma research
Shares Uveal melanoma, Melanoma.
- TrialIDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
Shares Uveal melanoma, Ipilimumab, Melanoma, Pembrolizumab.
- TrialA Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
Shares Uveal melanoma, Melanoma.